A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

A study to determine the ability of different doses of PF-610,355 to open the airways in asthmatic patients by comparison with placebo and a marketed drug that also opens the airways in asthmatic patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Salmeterol Xinafoate

Criteria

Inclusion Criteria:

• Reversible asthmatic patients (>15% increase in FEV1 following 200ug salbutamol).

• FEV1 greater than or equal to 60% predicted

• Stable disease for at least the previous 3 months

Exclusion Criteria:

• Subjects requiring rescue medication on greater than 2 occasions in the 72 hours prior to screening

• Subjects with a history of pulmonary disease other than asthma.